Lee Adrian Y S
Western Health, Melbourne, VIC, Australia.
School of Medicine, University of Tasmania, Hobart, TAS, Australia.
Rheumatol Int. 2017 Aug;37(8):1323-1333. doi: 10.1007/s00296-017-3718-1. Epub 2017 Apr 17.
Anti-Ro52/tripartite motif-containing 21 (TRIM21) is a ubiquitous antibody found in a number of systemic autoimmune conditions including Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis, appearing in about half of these patients. Once coupled with its closely related antibody, anti-Ro60 as the anti-SSA antibody, anti-Ro52 is emerging as a unique antibody with direct pathogenic disease involvement and distinct clinical properties. As a result, recent attention has turned to this antibody and its clinical associations and utility. There is a suggestion of anti-Ro52 being associated with more clinical and laboratory markers of disease; however, marked disagreements occur about its association with various clinical entities such as interstitial lung disease and Raynaud's phenomena. Nevertheless, with a relative paucity of studies about these across the systemic autoimmunity paradigm, limited confidence can be invested in these conclusions. Although the antibody holds great potential as a biomarker, further studies examining its clinical utility are needed. This paper will review the mechanisms of Ro52 as an autoantigen and the clinical associations of anti-Ro52 in human autoimmunity.
抗Ro52/含三联基序蛋白21（TRIM21）是一种在多种系统性自身免疫性疾病中普遍存在的抗体，这些疾病包括干燥综合征、系统性红斑狼疮和系统性硬化症，约半数此类患者体内会出现该抗体。抗Ro52一旦与其密切相关的抗体抗Ro60（即抗SSA抗体）结合，就会作为一种具有直接致病作用且临床特性独特的抗体而出现。因此，近来人们的注意力转向了这种抗体及其临床关联和用途。有迹象表明抗Ro52与更多疾病的临床和实验室指标相关；然而，对于其与诸如间质性肺病和雷诺现象等各种临床病症的关联，存在明显分歧。尽管如此，鉴于在系统性自身免疫范例中针对这些方面的研究相对较少，对这些结论的信心有限。虽然该抗体作为生物标志物具有巨大潜力，但仍需要进一步研究以检验其临床效用。本文将综述Ro52作为自身抗原的机制以及抗Ro52在人类自身免疫中的临床关联。
